Lonapegsomatropin is long-acting growth hormone (once-weekly) for the treatment of pediatric growth hormone deficiency (PGHD).

Lonapegsomatropin provides a convenient once-weekly dosing regimen, achieving up to 86% reduction in injection frequency compared to daily somatropin. It has demonstrated superiority and comparable safety compared to daily somatropin in the completed global and Chinese phase 3 pivotal trials.

Biologics License Application (BLA) of lonapegsomatropin has been accepted by China National Medical Products Administration (NMPA) for the treatment of PGHD. It is the first once-weekly administrated growth hormone approved by both the U.S. Food & Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of PGHD.